# Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-chemotherapy-as-first-line-treatment-in/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Martin Reck,Michael Schenker,Ki Hyeong Lee,Mariano Provencio,Makoto Nishio,Krzysztof Leśniewski-Kmak,Randeep Sangha,Samreen Ahmed,Judith Raimbourg,Kynan Feeney,R. Corre,Fábio Franke,Eduardo Richardet,John R. Penrod,Yong Yuan,Faith E. Nathan,Prabhu Bhagavatheeswaran,Michael DeRosa,Fiona Taylor,Rachael Lawrance,Julie R. Brahmer |
| Citations | 218 |
| DOI | 10.1016/j.ejca.2019.05.008 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | http://www.ejcancer.com/article/S0959804919303119/pdf |
| OpenAlex ID | https://openalex.org/W2949515538 |
| PMID | 31195357 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Judith Raimbourg](https://scholariq.org/researchers/judith-raimbourg/)
- [Julie R. Brahmer](https://scholariq.org/researchers/julie-r-brahmer/)

## Paper journal

- [European Journal of Cancer](https://scholariq.org/journals/european-journal-of-cancer/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.